Leo Pharma will not use acquisition option after candidate disappoints in phase III trial
Leo Pharma partner Pellepharm's drug patidegib has not generated sufficiently convincing phase III data for the dermatology group to utilize its acquisition option and take over the candidate – and the company.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
A Danish billion-kroner acquisition of Californian biotech company Pellepharm will not be happening.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
